A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy.

摘要: Patients with myelodysplastic syndrome (mds) experience clinical complications related to progressive marrow failure and have an increased risk of developing acute myeloid leukemia. Frequent red blood cell transfusion can lead iron overload is associated decreased survival in mds patients. Iron chelation therapy reduces markers prevents end-organ damage. Here, we present the case a patient low-risk transfusional overload. He was treated for 2 years oral chelator, deferasirox, after 12 months treatment, he experienced hemoglobin increase more than 50 g/L, becoming transfusion-independent. has remained transfusion-independent, normal level, since stopping therapy. Hematologic erythroid responses previously been reported patients chelation. The durability our patient’s response suggests that might alter natural history some